Table 1 Patients’ baseline and demographic data, stratified by baseline reliever use (<1, 1–2 and >2 occasions/day)
BUD/FORM MRT (All patients) (n = 626) | Fixed-dose BUD (All patients) (n = 613) | Baseline reliever use subgroup | ||||||
|---|---|---|---|---|---|---|---|---|
<1 occasion/day | 1–2 occasions/day | >2 occasions/day | ||||||
BUD/FORM MRT (n = 168) | Fixed-dose BUD (n = 155) | BUD/FORM MRT (n = 257) | Fixed-dose BUD (n = 253) | BUD/FORM MRT (n = 201) | Fixed-dose BUD (n = 205) | |||
Male, n (%) | 254 (40.6) | 227 (37.0) | 71 (42.3) | 58 (37.4) | 104 (40.5) | 100 (39.5) | 79 (39.3) | 69 (33.7) |
Age, year | 37.0 (15.9) | 38.3 (16.5) | 35.6 (15.7) | 37.5 (16.0) | 36.0 (16.2) | 37.7 (17.0) | 39.4 (15.5) | 39.6 (16.1) |
Duration of asthma, yearsa | 10 | 9 | 7 | 8 | 10 | 10 | 11 | 10 |
Dose of inhaled corticosteroid, μg/day BUD eqv | 357.8 (70.2) | 356.1 (70.8) | 339.9 (84.6) | 325.4 (88.1) | 359.9 (71.0) | 367.2 (63.2) | 370.1 (51.0) | 365.6 (57.4) |
Pre-BD FEV1 % predicted | 73.6 (10.9) | 73.0 (10.7) | 74.0 (11.2) | 74.0 (11.1) | 74.8 (10.6) | 73.4 (10.6) | 71.7 (10.6) | 71.7 (10.5) |
Post-BD FEV1 % predicted | 88.5 (12.6) | 88.0 (12.9) | 89.4 (12.9) | 89.0 (13.6) | 89.5 (11.7) | 88.5 (12.4) | 86.5 (13.2) | 86.8 (12.8) |
Baseline pre-BD FEV1, L | 2.41 (0.7) | 2.35 (0.7) | 2.51 (0.7) | 2.47 (0.7) | 2.46 (0.7) | 2.41 (0.8) | 2.26 (0.7) | 2.19 (0.7) |
Baseline FEV1 reversibility, % | 14.9 (7.5) | 15.0 (7.8) | 15.4 (7.0) | 15.0 (8.0) | 14.7 (7.6) | 15.0 (7.9) | 14.9 (7.9) | 15.1 (7.6) |
Current smoker/ex-smoker, n (%) | 117 (18.7) | 114 (18.6) | 26 (15.5) | 24 (15.5) | 52 (20.2) | 47 (18.6) | 39 (19.4) | 43 (21.0) |